	US 11,780,929 B2
	Immunomodulatory antibodies
Aymen Al-Shamkhani, Southampton (GB); Hak Tak Claude Chan, Southampton (GB); Mark Steven Cragg, Southampton (GB); Ruth Rosemary French, Southampton (GB); Martin John Glennie, Southampton (GB); and Jane Elizabeth Willoughby, Southampton (GB)
Assigned to Cancer Research Technology Limited, London (GB)
Filed by Cancer Research Technology Limited, London (GB)
Filed on Apr. 20, 2021, as Appl. No. 17/235,174.
Application 17/235,174 is a division of application No. 15/773,821, granted, now 11,001,638, previously published as PCT/EP2016/076747, filed on Nov. 4, 2016.
Claims priority of application No. 1519481 (GB), filed on Nov. 4, 2015.
Prior Publication US 2021/0317222 A1, Oct. 14, 2021 Prior Publication US 2022/0213207 A9, Jul. 7, 2022
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/02 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/02 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2039/57 (2013.01); A61K 2039/575 (2013.01); A61K 2039/80 (2018.08); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/75 (2013.01)]

3 Claims

1. An isolated monoclonal antibody or antigen binding portion thereof which specifically binds to the cysteine rich repeat sequences in extracellular domain 1 of 4-1BB, comprising:

(a) heavy chain CDRs having SEQ ID NO: 1-3 and light chain CDRs having SEQ ID NO: 4-6;

(b) heavy chain CDRs having SEQ ID NO: 7-9 and light chain CDRs having SEQ ID NO: 10-12; or